The new study included more than 120 men with metastatic castration-resistant prostate cancer, and was presented during the American Society of Clinical Oncology 2020 virtual meeting.

Tauvid was developed by Avid Radiopharmaceuticals, a subsidiary of Eli Lilly, and offers clinicians a new type of brain scan to use in patients being evaluated for Alzheimer's disease.

The radiopharmaceutical—Cerianna—is the first F-18 agent approved for use in patients with recurrent or metastatic breast cancer.

Stony Brook University investigators seek to quantify the precise degree of brain inflammation in those with the illness and ultimately hope to suggest novel treatments.

German scientists found six of seven patients with difficult-to-treat cancer had genetic mutations in their DNA damage-repair genes, according to new research.

Idaho Falls-based International Isotopes reported a 5% drop in revenue from nuclear medicine sales, primarily due to imaging clinics shutting their doors and suspending elective exams.

Vancouver, British Columbia-based Artms will use the funding to help bolster the supply of locally produced radioisotopes, such as technetium-99m.

Inflitration occurs when a a radiotracer is not safely injected into an individual's vein, but the true impact of these adverse events remains unknown to patients and physicians.

A novel radiotracer and synaptic imaging revealed "widespread" losses throughout the brain, Yale University researchers reported Wednesday.

Nuclear medicine experts found that 18F-PSMA-1007 performed just as well as 68Ga-PSMA for staging individuals with intermediate- or high-risk forms of the disease.

The fully digital modality can also offer insights into various neurodegenerative diseases, German researchers wrote. 

The Australian Nuclear Science and Technology Organization said its new scandium-47 radioisotope has applications in both PET and SPECT approaches.